WallStSmart

Keurig Dr Pepper Inc (KDP)vsPfizer Inc (PFE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Pfizer Inc generates 274% more annual revenue ($63.32B vs $16.94B). PFE leads profitability with a 11.8% profit margin vs 10.8%. KDP appears more attractively valued with a PEG of 0.97. KDP earns a higher WallStSmart Score of 61/100 (C+).

KDP

Buy

61

out of 100

Grade: C+

Growth: 4.7Profit: 6.0Value: 8.0Quality: 4.3
Piotroski: 5/9Altman Z: 1.06

PFE

Buy

55

out of 100

Grade: C

Growth: 3.3Profit: 7.0Value: 6.0Quality: 4.8
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

KDPUndervalued (+59.0%)

Margin of Safety

+59.0%

Fair Value

$72.90

Current Price

$28.83

$44.07 discount

UndervaluedFair: $72.90Overvalued
PFEUndervalued (+31.4%)

Margin of Safety

+31.4%

Fair Value

$37.44

Current Price

$25.68

$11.76 discount

UndervaluedFair: $37.44Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

KDP2 strengths · Avg: 8.0/10
PEG RatioValuation
0.978/10

Growing faster than its price suggests

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

PFE4 strengths · Avg: 8.8/10
Operating MarginProfitability
31.6%10/10

Strong operational efficiency at 31.6%

Market CapQuality
$150.92B9/10

Large-cap with strong market position

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$2.18B8/10

Generating 2.2B in free cash flow

Areas to Watch

KDP3 concerns · Avg: 2.3/10
Return on EquityProfitability
6.3%3/10

ROE of 6.3% — below average capital efficiency

EPS GrowthGrowth
-47.7%2/10

Earnings declined 47.7%

Altman Z-ScoreHealth
1.062/10

Distress zone — elevated risk

PFE3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
13.772/10

Expensive relative to growth rate

EPS GrowthGrowth
-10.1%2/10

Earnings declined 10.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : KDP

The strongest argument for KDP centers on PEG Ratio, Price/Book. PEG of 0.97 suggests the stock is reasonably priced for its growth.

Bull Case : PFE

The strongest argument for PFE centers on Operating Margin, Market Cap, Price/Book.

Bear Case : KDP

The primary concerns for KDP are Return on Equity, EPS Growth, Altman Z-Score.

Bear Case : PFE

The primary concerns for PFE are Piotroski F-Score, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

KDP carries more volatility with a beta of 0.42 — expect wider price swings.

KDP is growing revenue faster at 9.4% — sustainability is the question.

PFE generates stronger free cash flow (2.2B), providing more financial flexibility.

Monitor BEVERAGES - NON-ALCOHOLIC industry trends, competitive dynamics, and regulatory changes.

Bottom Line

KDP scores higher overall (61/100 vs 55/100). PFE offers better value entry with a 31.4% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Keurig Dr Pepper Inc

CONSUMER DEFENSIVE · BEVERAGES - NON-ALCOHOLIC · USA

Keurig Dr Pepper Inc. is a beverage company in the United States and internationally. The company is headquartered in Burlington, Massachusetts.

Pfizer Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Visit Website →

Want to dig deeper into these stocks?